Atherogenic Oxidized Low-Density Lipoprotein/β2-Glycoprotein I (oxLDL/β2GPI) Complexes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Oxidized low-density lipoprotein (oxLDL) interacts in vitro with β 2 -glycoprotein I ( β 2 GPI) via LDL-derived specific ligands forming oxLDL/ β 2 GPI complexes. Circulating oxLDL/ β 2 GPI complexes have been demonstrated in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Autoimmune vascular inflammation and oxidative stress contribute to oxLDL/ β 2 GPI complex formation. Immunohistochemical staining of atherosclerotic lesions suggest that these complexes are formed in the arterial wall and released into circulation. The demonstration of antibodies to oxLDL/ β 2 GPI complexes indicates that these complexes are immunogenic, and the coexistence of complexes and antibodies suggest an active pro-thrombotic/pro-atherogenic role in the development of autoimmune vascular complications. Circulating oxLDL/ β 2 GPI complexes can be measured by ELISA using a monoclonal antibody specific to complexed human β 2 GPI to capture β 2 GPI bound to oxLDL. An enzyme-conjugated monoclonal antibody to human Apo B 100 allows the specific detection of oxLDL/ β 2 GPI complexes. OxLDL/ β 2 GPI complexes were common in SLE and APS patients suggesting an underlying process of inflammation and oxidation. Using oxLDL/ β 2 GPI complexes as capture antigen, antibodies to oxLDL/ β 2 GPI can be measured by ELISA. Serum levels of IgG anti-oxLDL/ β 2 GPI antibodies were significantly higher in SLE patients with APS compared to SLE controls without APS. Further, high titers of these IgG antibodies were observed in APS patients with a history of arterial thrombosis. The presence of circulating oxLDL/ β 2 GPI complexes and IgG antibodies to these complexes indicates significant vascular injury and oxidative stress as well as an active role in autoimmune-mediated atherothrombosis.